From silent partners to potential therapeutic targets: macrophages in colorectal cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-03965-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Hayat Khizar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medici…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tumor-Associated Macrophages, Immunotherapy, Macrophages. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer cells grow and survive in the tumor microenvironment, which is a complicated process. As a key part of how colorectal cancer (CRC) progresses, tumor-associated macrophages (TAMs) exhibit a double role. Through angiogenesis, this TAM can promote the growth of cancers. Although being able to modify and adjust immune cells is a great advantage, these cells can also exhibit anti-cancer properties including direct killing of cancer cells, presenting antigens, and aiding T cell-mediated responses. The delicate regulatory mechanisms between the immune system and tumors are composed of a complex network of pathways regulated by several factors including hypoxia, metabolic reprogramming, cytokine/chemokine signaling, and cell interactions. Decoding and figuring out these complex systems become significant in building targeted treatment programs. Targeting TAMs in CRC involves disrupting chemokine signaling or adhesion molecules, reprogramming them to an anti-tumor phenotype using TLR agonists, CD40 agonists, or metabolic modulation, and selectively removing TAM subsets that promote tumor growth. Multi-drug resistance, the absence of an accurate biomarker, and drug non-specificity are also major problems. Combining macrophage-targeted therapies with chemotherapy and immunotherapy may revolutionize treatment. Macrophage studies will advance with new technology and multi-omics methodologies to help us understand CRC and build specific and efficient treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
- Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China. sypzju@zju.edu.cn.
- Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Jiefang Road 88th, Hangzhou, 3…
Förderung
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Khizar, H., Ali, K., & Wang, J. (2025). From silent partners to potential therapeutic targets: macrophages in colorectal cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03965-w
Vancouver
Khizar H, Ali K, Wang J. From silent partners to potential therapeutic targets: macrophages in colorectal cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03965-w
BibTeX
@article{Khizar2025,
author = {Khizar, Hayat and Ali, Kamran and Wang, Jianwei},
title = {From silent partners to potential therapeutic targets: macrophages in colorectal cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-03965-w}
}
EUVIMED